FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947304757> ?p ?o ?g. }

• W2947304757 abstract "6597 Background: ICI are used in the treatment of advanced malignancies with on-target adverse events of non-tumor inflammation. Many studies have shown conflicting safety results with regard to older vs younger adults where 65 - 70 years of age has been used as the discrete cut-off variable. We sought to investigate the incidence and the association between age and sirAE using age as a continuous variable at a large tertiary cancer center. Methods: Under IRB approval, our ICI outcomes database was queried for those who were hospitalized and received an immunosuppressant. Charts were individually reviewed to identify hospital admissions due to a sirAE (a grade 3 or 4 AE per CTCAE v4.0) and all-cause mortality at 12 months post ICI start. Non-linear analyses using Cox regression models with penalized smoothed splines were performed to explore association between age and sirAE. Results: There were 6.3% of 1043 patients who had a sirAE, and a total of 83 sirAE events. Mean age was 64± 13 years.ICI included anti-PD-1 (77.8%), anti-CTLA-4 (18.1%), and anti PD-L1 (4.1%). Pts with sirAE had a thirty day, and one year mortality of 12% and 49%, respectively. These events included: colitis (30.1%), pneumonitis (16.9%), hepatitis (10.8%), hypophysitis (6%), and thyroiditis (6%). There were 5 neurologic and 4 myocarditis/myositis sirAEs. The 1-year cumulative incidences of sirAE and all-cause mortality were 8.4%, and 48%, respectively. Spline analysis showed a U-shaped association between age and hazard of sirAE (P = 0.03). Every 10 years above age 60 was associated with increased sirAE (HR 1.65 [1.14-2.40], P = 0.008), while every 10 years below 60 was associated with increased sirAE (HR 1.50 [0.99-2.27], P = 0.054). However, age and mortality showed a linear association (P = 0.003). Conclusions: We observed a curvilinear U-shaped association between age and the risk of sirAE, with minimum risk at age of 60, compared with a linear relationship between age and mortality. Further studies are needed to understand this relationship and its impact on outcomes, clinical care, and underlying host immune context." @default.
• W2947304757 created "2019-06-07" @default.
• W2947304757 creator A5020594501 @default.
• W2947304757 creator A5041529923 @default.
• W2947304757 creator A5062453358 @default.
• W2947304757 creator A5070016877 @default.
• W2947304757 creator A5070044404 @default.
• W2947304757 creator A5074114750 @default.
• W2947304757 creator A5085025467 @default.
• W2947304757 creator A5088645680 @default.
• W2947304757 date "2019-05-20" @default.
• W2947304757 modified "2023-09-24" @default.
• W2947304757 title "Association between age, risk of severe (Grade 3-4) immune-related adverse events (sirAE), and mortality in patients receiving immune checkpoint inhibitors (ICI)." @default.
• W2947304757 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.6597" @default.
• W2947304757 hasPublicationYear "2019" @default.
• W2947304757 type Work @default.
• W2947304757 sameAs 2947304757 @default.
• W2947304757 citedByCount "0" @default.
• W2947304757 crossrefType "journal-article" @default.
• W2947304757 hasAuthorship W2947304757A5020594501 @default.
• W2947304757 hasAuthorship W2947304757A5041529923 @default.
• W2947304757 hasAuthorship W2947304757A5062453358 @default.
• W2947304757 hasAuthorship W2947304757A5070016877 @default.
• W2947304757 hasAuthorship W2947304757A5070044404 @default.
• W2947304757 hasAuthorship W2947304757A5074114750 @default.
• W2947304757 hasAuthorship W2947304757A5085025467 @default.
• W2947304757 hasAuthorship W2947304757A5088645680 @default.
• W2947304757 hasConcept C126322002 @default.
• W2947304757 hasConcept C143998085 @default.
• W2947304757 hasConcept C197934379 @default.
• W2947304757 hasConcept C203014093 @default.
• W2947304757 hasConcept C2777701055 @default.
• W2947304757 hasConcept C2780851360 @default.
• W2947304757 hasConcept C71924100 @default.
• W2947304757 hasConcept C8891405 @default.
• W2947304757 hasConceptScore W2947304757C126322002 @default.
• W2947304757 hasConceptScore W2947304757C143998085 @default.
• W2947304757 hasConceptScore W2947304757C197934379 @default.
• W2947304757 hasConceptScore W2947304757C203014093 @default.
• W2947304757 hasConceptScore W2947304757C2777701055 @default.
• W2947304757 hasConceptScore W2947304757C2780851360 @default.
• W2947304757 hasConceptScore W2947304757C71924100 @default.
• W2947304757 hasConceptScore W2947304757C8891405 @default.
• W2947304757 hasLocation W29473047571 @default.
• W2947304757 hasOpenAccess W2947304757 @default.
• W2947304757 hasPrimaryLocation W29473047571 @default.
• W2947304757 hasRelatedWork W2890262057 @default.
• W2947304757 hasRelatedWork W2942850106 @default.
• W2947304757 hasRelatedWork W2949494883 @default.
• W2947304757 hasRelatedWork W2956547457 @default.
• W2947304757 hasRelatedWork W2959224028 @default.
• W2947304757 hasRelatedWork W2977313374 @default.
• W2947304757 hasRelatedWork W2990069822 @default.
• W2947304757 hasRelatedWork W3015744343 @default.
• W2947304757 hasRelatedWork W3023708550 @default.
• W2947304757 hasRelatedWork W3034280928 @default.
• W2947304757 hasRelatedWork W3043779304 @default.
• W2947304757 hasRelatedWork W3093645502 @default.
• W2947304757 hasRelatedWork W3104085480 @default.
• W2947304757 hasRelatedWork W3122051635 @default.
• W2947304757 hasRelatedWork W3158326626 @default.
• W2947304757 hasRelatedWork W3169309829 @default.
• W2947304757 hasRelatedWork W3175742531 @default.
• W2947304757 hasRelatedWork W3185021648 @default.
• W2947304757 hasRelatedWork W3202959406 @default.
• W2947304757 hasRelatedWork W3214183670 @default.
• W2947304757 isParatext "false" @default.
• W2947304757 isRetracted "false" @default.
• W2947304757 magId "2947304757" @default.
• W2947304757 workType "article" @default.